Details of the Drug Combination

General Information of Drug Combination (ID: DCXOKDB)

Drug Combination Name
TG100-115 Sitosterol
Indication
Disease Entry Status REF
Hepatoblastoma Investigative [1]
Component Drugs TG100-115   DMON4IL Sitosterol   DM05DR0
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: HB3
Zero Interaction Potency (ZIP) Score: 7.758
Bliss Independence Score: 6.989
Loewe Additivity Score: 8.678
LHighest Single Agent (HSA) Score: 2.887

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of TG100-115
Disease Entry ICD 11 Status REF
Angioedema 4A00.15 Phase 1/2 [2]
Myocardial infarction BA41-BA43 Phase 1/2 [2]
TG100-115 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
PI3-kinase gamma (PIK3CG) TTHBTOP PK3CG_HUMAN Inhibitor [4]
------------------------------------------------------------------------------------
Indication(s) of Sitosterol
Disease Entry ICD 11 Status REF
Hyperlipidaemia 5C80 Approved [3]

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5715).
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic can... J Pharmacol Exp Ther. 2009 Mar;328(3):758-65.